Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bring On Clinical Studies: China Steps Up To Facilitate New Drug Entry

Executive Summary

Allowing early stage Phase I studies, setting a 60-day period for IND approvals, and dropping a requirement for hospital to get certified, the China FDA proposes fundamental changes that would allow any qualified sites to file for approval to get studies rolling.

You may also be interested in...



China FDA Proposes Sweeping Reforms To Incentivize Innovation

The China FDA releases a raft of new regulatory proposals outlining fundamental changes in areas including patent linkage and data exclusivity, which look set to profoundly impact decision makers looking at bringing new drugs and devices to the world’s second-largest pharma market.

Fake Clinical Data No More: China To Criminalize Forgery

China is planning to enact changes that will view the intentional forging of clinical trial and other data submitted to gain drug approvals as a criminal offence, punishable by prison terms of up to three years.

China Imposes Tough New Curbs On Rep Sales Activities

Tough new rules from China’s State Council have put the country’s one million medical reps into limbo as their employers scrabble to get to grips with broad curbs on sales activities.

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel